Trinity Biotech (NASDAQ:TRIB) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Trinity Biotech (NASDAQ:TRIBGet Rating) in a research note issued on Thursday. The firm set a “buy” rating on the stock.

Shares of TRIB stock opened at $1.28 on Thursday. Trinity Biotech has a 52-week low of $0.86 and a 52-week high of $3.98. The stock has a market cap of $26.75 million, a PE ratio of 14.22 and a beta of 1.33. The firm’s 50 day moving average price is $1.07 and its two-hundred day moving average price is $1.41.

Trinity Biotech (NASDAQ:TRIBGet Rating) last announced its quarterly earnings data on Monday, April 11th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.13). Trinity Biotech had a net margin of 0.94% and a negative return on equity of 27,745.46%.

Hedge funds have recently made changes to their positions in the business. Morgan Stanley boosted its position in shares of Trinity Biotech by 40.0% during the third quarter. Morgan Stanley now owns 20,765 shares of the company’s stock worth $45,000 after purchasing an additional 5,932 shares in the last quarter. Goldman Sachs Group Inc. bought a new position in shares of Trinity Biotech during the second quarter worth $32,000. LPL Financial LLC boosted its position in shares of Trinity Biotech by 20.1% during the fourth quarter. LPL Financial LLC now owns 106,973 shares of the company’s stock worth $153,000 after purchasing an additional 17,900 shares in the last quarter. Wealthsource Partners LLC bought a new position in shares of Trinity Biotech during the third quarter worth $65,000. Finally, Whitefort Capital Management LP bought a new position in shares of Trinity Biotech during the fourth quarter worth $50,000. 25.79% of the stock is currently owned by hedge funds and other institutional investors.

About Trinity Biotech (Get Rating)

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the United States, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.

Recommended Stories

Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.